In my opinion, Resverlogix is eligible for funds from the CAD 1 billion allocated by the Canadian government to development of treatments and vaccines related to Covid 19 (link; https://sciencebusiness.net/covid-19/news/canada-boost-covid-19-research-c1b). The proposal could/should be for running a trial in Covid-19 patients with pre-existing heart disease - here is why.

MACE is clearly a problem that is prevalent in Covid-19 patients (https://jamanetwork.com/journals/jamacardiology/fullarticle/2763844), and the patients at the highest risk have pre-existing heart problems and diabetes - so the patient population already tested in BETonMACE, would serve as a great data set for assuring safety.

Inflammation seems to be an overarching component for MACE in Covid-19 patients, as discussed in The Harvard Gazette, where doctors Libby and Ridker discuss the subject (https://news.harvard.edu/gazette/story/2020/04/covid-19s-consequences-for-the-heart/). Which again points at Apabetalone, which certainly seems to have an anti-inflammatory effect. Apabetalone may also have anti-coagulation effects, which also seems to be a problem in Covid 19 patients (https://www.medpagetoday.com/infectiousdisease/covid19/85577).

If the Canadian government wants a drug that reduces the mortality in hospitalized Covid-19, patients, Apabetalone is such an obvious choice.

I wrote IR last week to urge them to pursue this route of funding. I hope they have applied already (i.e. applied long before I wrote them), in which case I would think they have very good chances of getting funds. Otherwise, I hope that they'll seriously consider applying - this drug could very well be a game changer for mortality of Covid-19.

Having a breakthrough therapy designation from the FDA should boost the chances of getting funding, and we are are talking quite significant sums awarded to individual companies. Think about the impact on the stock price of Resverlogix if you replaced "Abcellera" with "Resverlogix" in the following headline:

"Abcellera receives 175.6 million from the government of Canada to discover solutions for covid-19...."

(the headline is bit longer - see link, but I trust that it is clear what I am trying to say).

https://www.abcellera.com/news/abcellera-receives-175.6-million-from-the-government 

Time will tell, but I do think that - as much as Covid 19 is a tragedy - it is also a golden opportunity for Resverlogix to prove that they have a blockbuster drug in Apabetalone.

Time will tell.

BR.

BKC